Results 1 to 10 of about 26,822 (186)

Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1/ACSL4 Axis

Frontiers in Pharmacology, 2022
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous cancer with increasing incidence. Itraconazole has been identified as a potential anticancer drug candidate. However, the role of itraconazole in cSCC was still unclear.
Congcong Xu, Yating Zhuo, Yunyao Liu, Hao Chen   +3 more
doaj   +1 more source

Gender differences in concentration of itraconazole and hydroxyitraconazole [PDF]

Halo 194, 2021
Introduction: Itraconazole is an antifungal drug belonging to the triazole group. After oral application, it is rapidly absorbed, but its bioavailability is reduced due to an intensive first-pass through the liver metabolism effect.
Stanojković Tijana, Miljković Milijana, Rančić Nemanja, Kovačević Aleksandra, Dragojević-Simić Viktorija   +4 more
doaj   +1 more source

The A756T Mutation of the ERG11 Gene Associated With Resistance to Itraconazole in Candida Krusei Isolated From Mycotic Mastitis of Cows

Frontiers in Veterinary Science, 2021
Candida krusei (C. krusei) has been recently recognized as an important pathogen involved in mycotic mastitis of cows. The phenotypic and molecular characteristics of 15 C.
Jun Du, Jun Du, Wenshuang Ma, Wenshuang Ma, Jiaqi Fan, Jiaqi Fan, Xiaoming Liu, Xiaoming Liu, Yujiong Wang, Yujiong Wang, Xuezhang Zhou, Xuezhang Zhou   +11 more
doaj   +1 more source

Itraconazole inhibits proliferation, induces apoptosis, and reduces angiogenesis of hemangioma endothelial cells by downregulating the hedgehog signaling pathway

Heliyon, 2023
Infantile hemangioma (IH) is among the most prevalent benign vascular tumours in infants. The pathogenesis of IH mainly involves abnormal proliferation of vascular endothelial cells and the formation of new vessels. Itraconazole was shown to be effective
Jianyong Dong, Jun Cui, Xuanxuan Shi, Tao Wang, Shaohua Liu   +4 more
doaj   +1 more source

Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei. [PDF]

PLoS ONE, 2015
To study the main molecular mechanisms responsible for itraconazole resistance in clinical isolates of Candida krusei.The 14α-demethylases encoded by ERG11 gene in the 16 C.krusei clinical isolates were amplified by polymerase chain reaction (PCR), and ...
Xiaoyuan He, Mingfeng Zhao, Jinyan Chen, Rimao Wu, Jianlei Zhang, Rui Cui, Yanyu Jiang, Jie Chen, Xiaoli Cao, Yi Xing, Yuchen Zhang, Juanxia Meng, Qi Deng, Tao Sui   +13 more
doaj   +1 more source

Cardiotoxicity with Itraconazole [PDF]

BMJ Case Reports, 2017
Itraconazole is a commonly used antifungal drug. In addition to commonly described adverse effects, there have been few reports of heart failure with its use. We present two cases that developed acute systolic heart failure with Itraconazole use. A man in his early 30s was admitted with worsening leg swelling and dyspnoea on exertion.
Vishesh, Paul, Harsh, Rawal
openaire   +2 more sources

Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial

EBioMedicine, 2021
Background: The antifungal drug itraconazole exerts in vitro activity against SARS-CoV-2 in Vero and human Caco-2 cells. Preclinical and clinical studies are required to investigate if itraconazole is effective for the treatment and/or prevention of ...
Laurens Liesenborghs, M.D., Isabel Spriet, Pharm.D., Dirk Jochmans, Ph.D., Ann Belmans, Ph.D., Iwein Gyselinck, M.D., Laure-Anne Teuwen, M.D., Sebastiaan ter Horst, Msc., Erwin Dreesen, Ph.D., Tatjana Geukens, M.D., Matthias M. Engelen, M.D., Ewout Landeloos, M.D., Vincent Geldhof, M.D., Helga Ceunen, Barbara Debaveye, Bert Vandenberk, M.D., Lorenz Van der Linden, Pharm.D., Sofie Jacobs, MSc., Lana Langendries, Msc., Robbert Boudewijns, Msc., Thuc Nguyen Dan Do, Msc., Winston Chiu, Msc., Xinyu Wang, Msc., Xin Zhang, Msc., Birgit Weynand, M.D., Thomas Vanassche, M.D., Timothy Devos, M.D., Geert Meyfroidt, M.D., Wim Janssens, M.D., Robin Vos, M.D., Pieter Vermeersch, M.D., Joost Wauters, M.D., Geert Verbeke, Ph.D., Paul De Munter, M.D., Suzanne J.F. Kaptein, Ph.D, Joana Rocha-Pereira, Ph.D., Leen Delang, Ph.D., Eric Van Wijngaerden, M.D., Johan Neyts, Ph.D., Peter Verhamme, M.D.   +38 more
doaj   +1 more source

Evaluation of virulence and drug resistance of Sporothrix globosa itraconazole-resistant strains in Galleria mellonella

Pifu-xingbing zhenliaoxue zazhi, 2020
Objective: To evaluate virulence of itraconazole-resistant Sporothrix globosa and its sensitivity to itraconazole in Galleria mellonella. Methods: Itraconazole-resistant strain and itraconazole-sensitive strain of S.
Jing ZHANG, Tai-long HE, Xiao-yan WU, Xiao-wen HUANG, Huai-qiu HUANG   +4 more
doaj   +1 more source

Influence of Gender, Body Mass Index, and Age on the Pharmacokinetics of Itraconazole in Healthy Subjects: Non-Compartmental Versus Compartmental Analysis

Frontiers in Pharmacology, 2022
Itraconazole is a triazole antifungal agent with highly variable pharmacokinetics, with not yet fully identified factors as the source of this variability.
Milijana N. Miljković, Milijana N. Miljković, Nemanja Rančić, Nemanja Rančić, Aleksandra Kovačević, Aleksandra Kovačević, Bojana Cikota-Aleksić, Bojana Cikota-Aleksić, Ivan Skadrić, Vesna Jaćević, Vesna Jaćević, Vesna Jaćević, Momir Mikov, Viktorija Dragojević-Simić, Viktorija Dragojević-Simić   +14 more
doaj   +1 more source

Significant elevation of free itraconazole concentration at onset of adverse effects: A case report

Clinical Case Reports, 2021
Free itraconazole and hydroxyitraconazole concentrations were markedly elevated despite almost no changes in total concentrations when itraconazole was discontinued due to adverse effects.
Ryota Tanaka, Yosuke Suzuki, Hiroyuki Matsumoto, Mari Yamasue, Kenji Umeki, Kazuhiko Hashinaga, Ryosuke Tatsuta, Kazufumi Hiramatsu, Katsuhiko Kamei, Jun‐ichi Kadota, Hiroki Itoh   +10 more
doaj   +1 more source